指南与共识血管炎

系统性文献综述为2018年EULAR大血管炎管理推荐更新提供证据:聚焦巨细胞动脉炎

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
指南 / 共识 · RMD Open · 2019-09-16

该系统性文献综述分析了截至2017年12月的证据,为2018年EULAR大血管炎管理推荐更新提供依据,聚焦巨细胞动脉炎(GCA)。快速诊断路径可降低永久性视力丧失风险,糖皮质激素应尽早启动但最佳方案证据不足,加用甲氨蝶呤或托珠单抗可减少复发和激素需求。

要点

  • 快速诊断路径显著降低GCA患者永久性视力丧失风险(LoE 2b)。
  • 尚无可靠的GCA诊断或预后生物标志物(LoE 3b)。
  • 加用甲氨蝶呤或托珠单抗减少复发率和糖皮质激素需求(LoE 1b)。

核心结论

  • 两项系统性文献综述为2018年EULAR大血管炎管理推荐更新提供了GCA管理的新证据。

研究设计与样本

  • 开展了两项系统性文献综述,分别涉及大血管炎的诊断/监测和治疗策略。
  • 检索Medline、Embase和Cochrane数据库,从建库至2017年12月31日。
  • 排除影像学证据,因已发表于专门的EULAR推荐中。

主要发现

  • 共纳入287篇合格文章,其中122项研究聚焦诊断/监测,165项聚焦治疗。
  • 快速诊断路径相比历史队列显著降低永久性视力丧失风险(LoE 2b)。
  • 尚无可靠的GCA诊断或预后生物标志物(LoE 3b)。
  • 系统性文献综述证实尽早启动糖皮质激素(GC)的有效性。
  • GCA患者剂量依赖性GC相关不良事件风险增加(LoE 3b)。

关键数值与推荐

  • 无高质量证据确定GC最合适的起始剂量、给药途径、减量和疗程(LoE 4)。

临床怎么用

  • 临床应实施快速诊断路径以降低GCA患者永久性视力丧失风险。
  • 应尽早启动糖皮质激素治疗,但需注意剂量依赖性不良事件风险。
  • 可考虑加用甲氨蝶呤或托珠单抗以减少复发和GC需求。

局限性

  • 影像学证据被排除,未纳入本综述分析。
  • GC最佳方案及GCA患者监测方面证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the current evidence for the management of large vessel vasculitis (LVV) to inform the 2018 update of the EULAR recommendations. METHODS: Two systematic literature reviews (SLRs) dealing with diagnosis/monitoring and treatment strategies for LVV, respectively, were performed. Medline, Embase and Cochrane databases were searched from inception to 31 December 2017. Evidence on imaging was excluded as recently published in dedicated EULAR recommendations. This paper focuses on the data relevant to giant cell arteritis (GCA). RESULTS: We identified 287 eligible articles (122 studies focused on diagnosis/monitoring, 165 on treatment). The implementation of a fast-track approach to diagnosis significantly lowers the risk of permanent visual loss compared with historical cohorts (level of evidence, LoE 2b). Reliable diagnostic or prognostic biomarkers for GCA are still not available (LoE 3b).The SLR confirms the efficacy of prompt initiation of glucocorticoids (GC). There is no high-quality evidence on the most appropriate starting dose, route of administration, tapering and duration of GC (LoE 4). Patients with GCA are at increased risk of dose-dependent GC-related adverse events (LoE 3b). The addition of methotrexate or tocilizumab reduces relapse rates and GC requirements (LoE 1b). There is no consistent evidence that initiating antiplatelet agents at diagnosis would prevent future ischaemic events (LoE 2a). There is little evidence to guide monitoring of patients with GCA. CONCLUSIONS: Results from two SLRs identified novel evidence on the management of GCA to guide the 2018 update of the EULAR recommendations on the management of LVV.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Monti S, Águeda AF, Luqmani RA, et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open. 2019. PMID: 31673411. doi:10.1136/rmdopen-2019-001003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。